Dopaminergic and glutamatergic signaling crosstalk in Huntington's disease neurodegeneration : the role of p25/cyclin-dependent kinase 5 by Paoletti, Paola et al.
Neurobiology of Disease
Dopaminergic and Glutamatergic Signaling Crosstalk in
Huntington’s Disease Neurodegeneration: The Role of p25/
Cyclin-Dependent Kinase 5
Paola Paoletti,1,2 Ingrid Vila,1,2Maria Rife´,1,2 Jose´ Miguel Lizcano,3 Jordi Alberch,1,2 and Silvia Gine´s1,2
1Departament de Biologia Cellular, Immunologia i Neurocie`ncies, Facultat de Medicina, Institut dInvestigacions Biome`diques August Pi i Sunyer and
2Centro de Investigacio´n Biome´dica en Red sobre Enfermedades Neurodegenerativas, Universitat de Barcelona, E-08036 Barcelona, Spain, and 3Institut de
Neurocie`ncies i Departament de Bioquímica i Biologia Molecular, Universitat Auto`noma de Barcelona, E-08193 Barcelona, Spain
Altered glutamatergic and dopaminergic signaling has been proposed as contributing to the specific striatal cell death observed in
Huntington’s disease (HD). However, the precise mechanisms by which mutant huntingtin sensitize striatal cells to dopamine and
glutamate inputs remain unclear. Here, we demonstrate in knock-in HD striatal cells that mutant huntingtin enhances dopamine-
mediated striatal cell death via dopamineD1 receptors.Moreover, we show that NMDA receptors specifically potentiate the vulnerability
ofmutant huntingtin striatal cells to dopamine toxicity as pretreatment with NMDA increased D1R-induced cell death inmutant but not
wild-type cells. As potential underlying mechanism of increased striatal vulnerability, we identified aberrant cyclin-dependent kinase 5
(Cdk5) activation. We demonstrate that enhanced Cdk5 phosphorylation and increased calpain-mediated conversion of the Cdk5 acti-
vator p35 into p25 may account for the deregulation of Cdk5 associated to dopamine and glutamate receptor activation in knock-in HD
striatal cells.Moreover, supporting a detrimental role of Cdk5 in striatal cell death, neuronal loss can bewidely prevented by roscovitine,
a potent Cdk5 inhibitor. Significantly, reduced Cdk5 expression together with enhanced Cdk5 phosphorylation and p25 accumulation
also occurs in the striatum of mutant HdhQ111 mice and HD human brain suggesting the relevance of deregulated Cdk5 pathway in HD
pathology. These findings provide new insights into the molecular mechanisms underlying the selective vulnerability of striatal cells in
HD and identify p25/Cdk5 as an important mediator of dopamine and glutamate neurotoxicity associated to HD.
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Introduction
Huntington’s disease (HD) is a progressive neurological disorder
characterized by chorea, cognitive decline, and psychiatric dis-
turbances (MacDonald et al., 2003; Pe´rez-Navarro et al., 2006).
Dysfunction and death of striatal medium-spiny neurons is the
major feature of neuropathological changes in HD (Martin and
Gusella, 1986; de la Monte et al., 1988). Although it is not known
why spiny neurons are preferentially targeted for degeneration,
there is evidence to support the idea that mutant huntingtin tox-
icitymay involve excitotoxicity caused by aberrantNMDA recep-
tor activation (Pe´rez-Navarro et al., 2006; Fan and Raymond,
2007). In addition to glutamatergic afferents, the striatum also
receives the densest dopaminergic innervation in the brain from
the ventral midbrain neurons. Despite the high concentration of
dopamine (DA) in the striatum, a number of studies have re-
vealed a potential toxic role of DA in the nervous system (Jakel
and Maragos, 2000). Thus, exposure of primary striatal neurons
to DA causes significant neurotoxicity with increased free radical
production and accelerated neuronal death (Wersinger et al.,
2004). Moreover, there is increasing evidence that the dopami-
nergic systemmay contribute to HD neuropathology. Data from
striatal primary neurons that express exon-1 mutant huntingtin
indicates that DA exacerbates mutant huntingtin toxicity via re-
active oxygen species production and D2 receptor activation
(Charvin et al., 2005; Benchoua et al., 2008). Furthermore, in
doublemutantmice expressing endogenous levels of exon-1mu-
tant huntingtin and knock-out for the dopamine transporter, DA
accelerates protein aggregation and motor dysfunction (Cyr et
al., 2006). These data suggest that disturbed DA and NMDA sig-
naling may participate in the enhanced sensitivity of striatal neu-
rons to huntingtin toxicity. In this line, Tang et al. (2007) have
reported that dopamine potentiates glutamate-induced apopto-
sis in cultured striatal neurons from YAC128HDmice via activa-
tion of D1 receptors. However, little is known about the molecu-
lar mechanisms that underlie the increased vulnerability of
mutant huntingtin striatal cells to dopamine and glutamate
inputs.
Cyclin-dependent kinase 5 (Cdk5) is a serine/threonine ki-
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nase whose activity is primarily restricted to the nervous system
where its main activator p35 is expressed. Although Cdk5 is es-
sential for brain development, many neurodegenerative diseases
involve sustained activation of Cdk5 in neurons (Cruz and Tsai,
2004; Dhariwala and Rajadhyaksha, 2008). Several studies indi-
cate that Cdk5 becomes a cell death inductor when it binds to
p25, the calpain-mediated cleaved product of p35 (Lee et al.,
2000). Thus, accumulation of p25 has been observed in neurons
treated with glutamate or oxidative stress as well as in animal
models of several neurodegenerative diseases (Cruz and Tsai,
2004; Dhariwala and Rajadhyaksha, 2008). Notably, treatment
with 3-nitropropionic, the systemic administration ofwhich pro-
duces selective striatal degeneration with symptoms resembling
those of HD (Beal et al., 1993), induces striatal but not cortical
Cdk5 activation (Crespo-Biel et al., 2007; Akashiba et al., 2008).
More recently, it has been postulated for Cdk5 a role in dopami-
nergic neurodegeneration. Thus, 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP)-induced dopaminergic cell loss in-
volves enhancedCdk5 activity and increased conversion of p35 to
the pathogenic p25 form (Smith et al., 2003, 2006).
The above observations prompted us to explore the involve-
ment of aberrant glutamatergic and dopaminergic signaling in
striatal neurodegeneration in HD to determine whether Cdk5
might account for this neurotoxic effect. Our data suggest that
mutant huntingtin alters NMDAR andD1R signaling via Cdk5 to
increase the vulnerability of striatal cells to neurotoxicity.
Materials andMethods
Reagents and antibodies. NMDA, ()-SKF-38393 hydrochloride, ()-
Quinpirole dihydrochloride, R()-SCH-23390 hydrochloride, (-)-MK-
801 hydrogen maleate, EGTA, roscovitine, and SP600125 were obtained
from Sigma-Aldrich. Hoechst 33258 pentahydrate was from Invitrogen.
Anti-p35 (C-19), anti-phospho-Cdk5 (Tyr15), and anti-Cdk5 (J-3) anti-
bodies were purchased from Santa Cruz Biotechnology. Anti-phospho-
stress-activated protein kinase (SAPK)/c-Jun N-terminal protein kinase
(JNK) (Thr183/Tyr 185) and anti-SAPK/JNK were from Cell Signaling
Technologies. Paired helical filament (PHF)-1 and TG5 anti-tau anti-
bodies were a generous gift from Peter Davis (Albert Einstein College of
Medicine, Bronx, NY). Anti-green fluorescent protein (GFP) was ob-
tained from Clontech. Anti--spectrin was purchased from Millipore.
Anti--tubulin was from Sigma-Aldrich.
Cell cultures. Conditionally immortalized wild-type STHdhQ7 and
mutant STHdhQ111 striatal neuronal progenitor cell lines expressing en-
dogenous levels of normal and mutant huntingtin with 7 and 111 glu-
tamines, respectively, have been described previously (Trettel et al.,
2000). Striatal cells were grown at 33°C in DMEM (Sigma-Aldrich), sup-
plemented with 10% fetal bovine serum (FBS), 1% streptomycin-
penicillin, 2 mM L-glutamine, 1 mM sodium pyruvate, and 400 g/ml
G418 (Geneticin; Invitrogen).
GeneticHuntington’s diseasemousemodel and postmortembrain tissues.
HdhQ111 knock-in mice expressing mutant huntingtin with 111 glu-
tamine residues have been described previously (Wheeler et al., 1999).
Animals were deeply anesthetized with CO2 and decapitated. Striatum
was dissected from 9-month-old homozygousmutantHdhQ111/Q111 and
wild-type HdhQ7/Q7 littermate offspring, obtained from the mating of
male and female HdhQ111/Q7 heterozygotes. The animals were housed
under a 12 h light/dark cycle with food and water ad libitum. All proce-
dures were performed in accordance with the National Institutes of
Health and were approved by the local animal care committee of the
Universitat de Barcelona (99/01) and the Generalitat de Catalunya
(00/1094).
Samples of the caudate and putamen nucleus from three patients with
HD (with death at end-stage disease at 71, 68, and 65 years, postmortem
intervals of 4–15 h) and three control cases (42, 77, and 74 years, post-
mortem intervals of 4–23 h) were supplied by the Banc de Teixits Neu-
rolo`gics (Servei Científico-Te`cnic, Universitat de Barcelona, Barcelona,
Spain). All of the ethical guidelines contained within the latest Declara-
tion of Helsinki were taken into consideration, and informed consent
was obtained from all subjects under study.
Drug treatments of striatal cell lines. To induce NMDA excitotoxicity,
wild-type STHdhQ7 and mutant knock-in STHdhQ111 striatal cells were
exposed to 500 or 50 M NMDA in Locke’s solution (154 mM NaCl, 5.6
mM KCl, 2.3 mM CaCl2, 3.6 mMNaHCO3, 5 mMHEPES, 5.6 mM glucose,
and 10Mglycine) for 30min. After treatment, themediumwas replaced
by fresh DMEMmedium with 2.5% FBS.
To assess the effect of dopamine receptor activation, wild-type STH-
dhQ7 and mutant STHdhQ111 striatal cells were treated for 24 h in
DMEM medium (2.5% FBS) with different concentrations of the D1
receptor agonist SKF38393 (30, 60, 80, or 100 M) or the D2 receptor
agonist quinpirole (30, 60, or 150 M).
In some experiments, cultures were treated with the D1 receptor an-
tagonist (SCH-23390, 10 M), the JNK inhibitor (SP600125, 10 M), or
the Cdk5 inhibitor (roscovitine, 20 M) 1 h before NMDA or SKF38393
treatments.
To study Cdk5 and p35/p25 protein levels, wild-type STHdhQ7 and
mutant knock-in STHdhQ111 striatal cells were first placed in DMEM
serum-freemedium for 3 h. For theNMDA treatment, cells were exposed
to 500 M NMDA in Locke’s solution for 30 min. After treatment, the
mediumwas replaced by freshDMEMserum-freemedium, and total cell
extracts were obtained at different time periods (5, 15, 30, and 60 min).
For the SKF38393 treatment, cells were exposed to Locke’s solution for
30 min before the addition of SKF38393 (100 M) in fresh DMEM
serum-free medium. Total extracts were obtained at different time peri-
ods (5, 15, 30, and 60 min) after SKF38393 treatment. Finally, to assess
the combined treatment, cells were pre-exposed to 500 M NMDA in
Locke’s solution for 30 min. After treatment, the medium was replaced
by fresh DMEM serum-free medium containing 100 M SKF38393 and
total cell extractswere obtained at different timeperiods (5, 15, 30, and 60
min) after SKF38393 treatment.
To test the role of calcium influx in the p35/p25 protein levels, mutant
STHdhQ111 striatal cells were first placed in DMEM serum-free me-
dium for 3 h and then exposed to 25 M MK-801 or 400 M EGTA in
DMEM serum-free medium for 6 h. Total cell extracts were obtained
after treatment.
Cell survival. Cell survival was assessed by nuclear DNA staining with
Hoechst 33258. Cells were washed twice with PBS, fixed with 4% para-
formaldehyde in PBS for 10 min, washed twice in PBS, and stained with
Hoechst 33258 (1g/ml) for 5min. Stained cells were then washed twice
with PBS andmounted under glass coverslips withMowiol. Cell survival
is represented as the proportion of Hoechst-stained nuclei counted in
treated cells compared with the number of control (vehicle-treated) cells
(100%). Forty fields were counted per condition and experiment, com-
prising at least 30–40 cells. Data are given as mean  SD of values
obtained in three independent experiments performed in triplicate.
Cell transfection. For the study of polyQ length-dependent Cdk5 and
p-Cdk5 expression, wild-type STHdhQ7 striatal cells were transfected
using Lipofectamine 2000 as described by the manufacturer (Invitro-
gen).Wild-type STHdhQ7 at 50% confluencewere transfectedwith three
different constructs containing themutant exon 1 of the huntingtin gene
with different CAG/CAA repeats andwith enhancedGFP: 23,Q23htt; 72,
Q72htt and 103, Q103htt (Kazantsev et al., 1999) (generously provided
byDr. GeorgeM. Lawless, CureHD Initiative, Reagent Resource Bank of
theHereditaryDisease Foundation,NewYork,NY). The protein extracts
were prepared 24 h after transfection.
Western blot analysis. Total cellular extracts were collected in lysis
buffer containing 50 mM Tris base, pH 7.4, 150 mM NaCl, 2 mM EDTA,
0.1 mM phenylmethylsulphonyl fluoride, 1% NP-40, and supplemented
with 1 mM sodium orthovanadate and protease inhibitor mixture
(Sigma-Aldrich). Samples were centrifuged at 10,000 g for 10 min and
the protein contents determined by (detergent-compatible) protein as-
say (Bio-Rad). Protein extracts (20–40 g) were mixed with 5 SDS
sample buffer, boiled for 5 min, resolved by 8–10% SDS-PAGE, and
transferred to nitrocellulose membranes (Whatman Schleicher and
Schuell). Blots were blocked in 10% nonfat powdered milk in TBS-T (50
mM Tris-HCl, 150 mM NaCl, pH 7.4, 0.05% Tween 20) for 30 min at
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room temperature. The membranes were then incubated overnight at
4°C with primary antibodies [phospho-JNK (Thr183/Tyr 185) (1:1000),
total JNK (1:1000), p35 (1:1000), phospho-Cdk5 (Tyr15) (1:5000), total
Cdk5 (1:1000), GFP (1:500), -spectrin (1:1000), TauG5 (1:500), PHF-1
(1:500), or-tubulin (1:50,000)]. Themembraneswere then rinsed three
times with Tris-buffered saline–Tween 20 (TBS-T) and incubated with
horseradish peroxidase-conjugated secondary antibody for 1 h at room
temperature. After washing for 30min with TBS-T, themembranes were
developed using the enhanced chemiluminescence substrate kit (Santa
Cruz Biotechnology). The Gel-Pro densitometry program (Gel-Pro An-
alyzer for Windows, version 4.0.00.001) was used to quantify the differ-
ent immunoreactive bands relative to the intensity of the-tubulin band
in the samemembranes.We ensured signals were within a linear range of
detection for the ECL reagent on Hyperfilm ECL (GE Healthcare) by
probing increasing amounts of lysatewith the relevant antibody.Data are
expressed as the mean SD of band density obtained in three indepen-
dent experiments.
Cdk5 kinase activity. Cdk5 was immunoprecipitated with 1g of anti-
Cdk5 agarose conjugated antibody (C-8; Santa Cruz Biotechnology)
from 500 g of total cell lysates obtained from wild-type STHdhQ7 and
mutant STHdhQ111 striatal cells treated with 100 M SKF38393 alone or
pre-exposed (30 min) to NMDA before SKF38393 treatment. The im-
munoprecipitates were washed three times with lysis buffer and twice
with kinase buffer (50mMTris, pH7.5, 0.1%-mercaptoethanol, 0.1mM
EGTA, 0.1mMEDTA). The standard assay contained the following (50l
total volume): washed agarose immunoprecipitate, 50 mM Trs-HCl, pH
7.5, 0.1mM EGTA, 0.1%-mercaptoethanol, 10mMmagnesium acetate,
0.1mM [- 32P]-ATP (5Ci), and 200Mof substrate (peptide histone 1;
Jena Bioscience). The assays were performed for 60 min at 30°C, and the
assay tubes were agitated continuously to keep the immunoprecipitate in
suspension. Incorporation of [- 32P]-phosphate into peptide substrate
was determined using p81 phosphocellulose paper. Papers were washed
in 0.5% ortophosphoric acid, dried, and Cherenkov radiation was
counted. Control experiments were performed in parallel without the
peptide substrate.
Statistical analysis. All of the data were analyzed with the program
Graph Pad Prism version 4.0 (GraphPad Software). Results are expressed
as mean  SD. Experimental data were analyzed either by a one- or
two-way ANOVA followed by the post hoc Bonferroni’s multiple com-
parison test or by Student’s t test. A value of p  0.05 was accepted as
denoting statistical significance.
Results
D1 receptor activation increases neuronal death in
STHdhQ111 striatal cells
To determine whether mutant huntingtin enhances the vulnera-
bility of striatal cells to dopamine, immortalized striatal cells ex-
pressing endogenous levels of full-length wild-type STHdhQ7 or
mutant STHdhQ111 huntingtin were treated with increasing con-
centrations of the D1 receptor agonist SKF38393 (0–100 M) or
the D2 receptor agonist quinpirole (0–150 M) followed by the
determination of cell survival. SKF38393 treatment caused a
dose-dependent increase in neuronal cell death in both wild-type
andmutant striatal cells (Fig. 1A). Two-way ANOVA analysis for
drug treatment and genotype showed that the effect was statisti-
cally significant (F(4,15) 444.30, p 0.001; F(1,15) 192.04, p
0.001, respectively). Importantly, the interaction between geno-
type and treatment was also statistically significant (F(4,15) 
31.69; p  0.001), indicating that the two cell genotypes re-
sponded differently to the SKF38393 treatment. Thus, at all
SKF38393 concentrations tested, the reduction in cell survival
was significantly higher in mutant STHdhQ111 than it was in
wild-type STHdhQ7 cells, with a maximal difference detected at
100M SKF38393 (wild type, 64 11% vsmutant, 39 6%; p
0.001). It should be noted that (1) at the lower tested concentra-
tion (SKF38393 30M) only mutant huntingtin STHdhQ111 cells
exhibited a reduction in cell survival (20%; p 0.001), and (2)
the decrease in cell survival in STHdhQ7 wild-type cells reached a
maximum at 80 M SKF38393 (64  11%; p  0.001), whereas
STHdhQ111 mutant cells still exhibited higher cell death at 100
M SKF38393 (8%more compared with 80M SKF38393; p
0.05). Importantly, coincubation with the D1-selective antago-
nist SCH23390 significantly reduced SKF38393-induced cell
death near to that of control levels in both wild-type and mutant
huntingtin cells (85 10% and 79 11%; p 0.001, respec-
tively) (Fig. 1B). No effect on neuronal survival was observed
after stimulation of D2 receptors with quinpirole (Fig. 1A). Thus,
our results imply that D1 receptor activation mediates the dopa-
minergic toxic effect observed in wild-type andmutant knock-in
striatal cells and that full-length mutant huntingtin expression
potentiates dopamine-cell death through D1 but not D2
receptors.
Figure 1. Increased dopamine D1-receptor-mediated cell death in STHdh
Q111 striatal cells.
A, Wild-type (ST7/7Q) and mutant (ST1111/111Q) striatal cells were treated with different
concentrations of the D1 receptor agonist SKF38393 (30, 60, 80, or 100M) or the D2 receptor
agonist quinpirole (30, 60, or 150M) during 24 h. After treatment, cell survival wasmeasured
by scoring thepercentageofHoechst-stainednuclei. Forty fieldswere countedper conditionper
experiment, comprising at least 30–40 cells. Results are expressed as percentage of control
(vehicle-treated) cells, and data are the mean SD of three independent experiments per-
formed in triplicate. A full statistical analysis by the two-way ANOVA is described in the text.
***p 0.001 treated versus vehicle-treated wild-type cells; p 0.001 treated versus
vehicle-treated mutant cells; ##p 0.01, ###p 0.001 treated mutant cells versus treated
wild-type cells (Bonferroni’s multiple comparison test). CNT, Control. B, Wild-type andmutant
striatal cells were treated (1 h) with the D1 receptor antagonist SCH23390 (10 M) before
SKF38393 treatment (100M). Cell survivalwasassessed24h later by scoring thepercentageof
Hoechst-stained nuclei. Forty fields were counted per condition per experiment, comprising at
least 30–40 cells. Results are expressed as percentage of control (vehicle-treated) cells, and
data are the mean SD of three independent experiments performed in triplicate. ***p
0.001 treated versus vehicle-treated wild-type cells; p 0.001 treated versus vehicle-
treated mutant cells; $$$p 0.001 SCH23390 plus SKF38393-treated wild-type cells versus
SKF38393-treated wild-type cells; &&&p 0.001 SCH23390 plus SKF38393-treated mutant
cells versus SKF38393-treated mutant cells as determined by one-way ANOVA followed by
Bonferroni’s multiple comparison test.
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NMDA enhances dopamine D1 receptor-mediated cell death
selectively in STHdhQ111 cells
Previous results from our laboratory have demonstrated that
mutant STHdhQ111 striatal cells display enhanced sensitivity to
NMDA receptor activation (Xifro´ et al., 2008). Therefore, we
next analyzed whether NMDA treatment potentiates the neuro-
toxic effect of dopamine. We first analyzed the role of a toxic
concentration of NMDA (500 M) on cell death induced by D1R
activation. Wild-type STHdhQ7 and mutant STHdhQ111 striatal
cells were exposed for 30 min to NMDA before SKF38393 treat-
ment, and cell survival was analyzed 24 h later. Pretreatment with
NMDA failed to increase SKF38393-induced cell death in wild-
type STHdhQ7 cells (Fig. 2A). Two-way ANOVA for SKF38393
treatment and wild-type group (control and pretreated with
NMDA) showed that the effect was statistically significant for
drug treatment (F(3,12) 285.6; p 0.001) but not for wild-type
group (F(1,12) 0.97; p 0.33). Two-way ANOVA analysis also
revealed lack of interaction between factors (F(3,12)  0.38; p 
0.77). In contrast, mutant STHdhQ111 striatal cells exhibited a
significant decrease in cell survival rates when pre-exposed to
NMDA comparedwith SKF38393 treatment alone (Fig. 2A). Sta-
tistical analysis revealed a main effect of NMDA pretreatment in
SKF38393-induced cell death in mutant huntingtin striatal cells
[F(3,12) 740.23, p 0.001 for SKF38393
treatment; F(1,12)  97.07, p  0.001 for
mutant group (control and pretreated
withNMDA)].Notably, two-wayANOVA
analysis also revealed a statistically signifi-
cantmutant group SKF38393 treatment
interaction (F(3,12) 13.4; p 0.001), in-
dicating that mutant huntingtin cells re-
sponded differently to SKF38393 treat-
ment when pre-exposed to NMDA toxic
concentrations (Fig. 2A). It is important
to remark that this effect was observed at
concentrations of both SKF38393 and
NMDA that induced moderate cell death.
To analyze further the effect of NMDA
and SKF38393 on striatal cell death, we
next evaluated whether a subtoxic concen-
tration of NMDA (50 M) modulates
D1R-mediated cell death. Consistent with
the lack of an additive effect at toxic
NMDA concentrations, wild-type STH-
dhQ7 striatal cells pretreated with 50 M
NMDA did not show increased cell death
to that reported for SKF38393 treatment
alone (Fig. 2B). Two-way ANOVA for
SKF38393 treatment and wild-type group
(control and pretreated with NMDA)
showed that the effect was statistically sig-
nificant for drug treatment (F(3,12) 
814.7; p  0.001) but not for wild-type
group (F(1,12) 0.92; p 0.35). No inter-
action between factors was demonstrated
by two-way ANOVA analysis (F(3,12) 
0.30; p 0.82). Interestingly, NMDA pre-
exposure was still found to potentiate the
cell death induced by SKF38393 treatment
in mutant STHdhQ111 striatal cells [F(1,12)
 481.68, p  0.001 for SKF38393 treat-
ment; F(1,12) 49.6, p 0.001 for mutant
group (control and pretreated with
NMDA)]. Moreover, two-way ANOVA analysis showed that the
interaction between factors was statistically significant (F(3,12)
9.07; p  0.001), which indicates that the curve of dose-
dependent cell death induced by SKF38393 was different in mu-
tant cells when pre-exposed to subtoxic NMDA concentrations.
Together, these data indicate thatNMDAenhances the sensibility
of mutant but not wild-type striatal cells to D1 receptor
activation.
JNK activation is not associated with NMDA and SKF38393-
mediated neurotoxicity in STHdhQ111 cells
Activation of the JNKmay contribute to neuronal cell death after
excitotoxicity (Brecht et al., 2005; Centeno et al., 2007). To inves-
tigate the potential role of the JNK pathway in the neurotoxic
effect of NMDA and SKF38393, wild-type STHdhQ7 and mutant
STHdhQ111 striatal cells were treated with 500MNMDA or 100
M SKF38393, and the levels of total and phospho-JNK were
determined by Western blot analysis. The immunoblot results
revealed that neither NMDA nor SKF38393 exposure induced
phosphoactivation of JNK (Fig. 3A). Moreover, analysis of wild-
type and mutant cells exposed to 500 M NMDA for 30 min
before SKF38393 treatment revealed that a combination of both
drugs did not increase JNK phosphorylation either (Fig. 3A). In
Figure 2. NMDA potentiates the toxic effect of D1-receptor activation in STHdh
Q111 striatal cells. A, Wild-type (ST7/7Q) and
mutant (ST111/111Q) striatal cells were treated with a toxic concentration of NMDA (500M) for 30 min before treatment with
different concentrations of SKF38393 (60, 80, or 100 M). Cell survival was assessed 24 h later by scoring the percentage of
Hoechst-stained nuclei. B, Wild-type andmutant striatal cells were exposed to a subtoxic concentration of NMDA (50M) for 30
min before treatment with different concentrations of SKF38393 (30, 60, or 100M). Cell survival was measured 24 h later by
scoring the percentage of Hoechst-stained nuclei. Forty fields were counted per condition per experiment, comprising at least
30–40 cells. Results are expressed as percentage of control (vehicle-treated) cells, and data are the mean  SD of three
independent experiments performed in triplicate. A full statistical analysis by the two-way ANOVA is described in the text. **p
0.01, ***p0.001 treated versus vehicle-treatedwild-type cells; p0.01, p0.001 treated versus vehicle-treated
mutant cells; #p 0.05, ##p 0.01, ###p 0.001 NMDAplus SKF38393-treatedmutant cells versus SKF38393-treatedmutant
cells (Bonferroni’s multiple comparison test).
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line with the lack of phospho-JNK activa-
tion, pre-exposure of wild-type STHdhQ7
andmutant STHdhQ111 huntingtin cells to
10 M SP600125, a JNK inhibitor, did not
rescue wild-type ormutant cells fromneu-
rotoxic cell death mediated by NMDA or
SKF38393 or both (Fig. 3B). These results
indicate that JNK does not participate in
the observed neurotoxicity induced by
NMDAorD1R activation in STHdh
Q7 and
STHdhQ111 cells.
NMDA potentiates D1R-induced
phosphorylation of Cdk5 in mutant
STHdhQ111 cells
Deregulation of Cdk5 activity has been as-
sociated to neuronal cell death in several
neurodegenerative disorders (Cruz and
Tsai, 2004). To determine whether Cdk5
activation was involved in the increased
vulnerability of mutant STHdhQ111 cells
to NMDAR and D1R activation, we first
analyzed the levels of total and phosphor-
ylated Cdk5 (Tyr 15) in extracts obtained
from wild-type STHdhQ7 and mutant
STHdhQ111 striatal cells (Fig. 4A). Immuno-
blot analysis revealed that total Cdk5 levels
were lower inmutant cells than they were in
wild-type cells (2-fold; p  0.001),
whereas the levels of p-Tyr15 Cdk5 were
slightly increased (1.2-fold; p  0.05).
Therefore, a significant 3-fold increase in
the p-Tyr15 Cdk5/Cdk5 ratio ( p  0.001)
was apparent in mutant cells compared with wild-type cells.
To determine whether deregulation of Cdk5 pathway was de-
pendent onmutant huntingtin expression, wild-type striatal cells
were transfected with different constructs encoding for green flu-
orescent protein-tagged exon-1 mutant huntingtin protein with
23, 72, or 103 CAG repeats (Q23, Q72, and Q103), and total
extracts were analyzed by Western blot. The results, shown in
Figure 4B, revealed an inverse relationship between changes in
Cdk5 and the length of the CAG repeat. Thus, reduced Cdk5
expression along with higher Tyr15-Cdk5 phosphorylation was
found in wild-type striatal cells transfected with 72 or 103 poly-Q
containing exon-1 mutant huntingtin compared with those
transfected with the normal poly-Q length (Q23). These data
suggest that changes on Cdk5 pathway are directly dependent on
mutant huntingtin expression.
We next analyzed whether activation of NMDA andD1 recep-
tors was associated with changes in Cdk5 expression and phos-
phorylation. Exposure of wild-type STHdhQ7 and mutant STH-
dhQ111 striatal cells to NMDA resulted in a similar time-
dependent increase in Cdk5 phosphorylation. Statistical analysis
using two-way ANOVA revealed a significant time interval effect
(F(4,25)  16.03; p  0.001) without differences between geno-
types (F(1,25) 3.57; p 0.08) (Fig. 4C). The analysis also dem-
onstrated no interaction between factors (F(4,25) 0.57; p 0.7).
Thus, the increase inCdk5 phosphorylationwas already evident at 5
min,maximal at 15min, and remained high even 60min after treat-
ment. Incontrast, in thepresenceof100MSKF38393, thekineticof
Cdk5phosphorylationdiffered inmutant STHdhQ111andwild-type
STHdhQ7 cells (Fig. 4D). Statistical analysis using two-wayANOVA
revealed a significant effect of genotype (F(1,25) 39.36; p 0.001)
and time (F(4,25) 11.85; p 0.001) and a significant genotype
treatment interaction (F(4,25)  20.16; p  0.001), which demon-
strates that the time-dependent phosphorylation of Cdk5 induced
by SKF38393 differs between wild-type andmutant huntingtin stri-
atal cells. Thus, wild-type STHdhQ7 cells and mutant STHdhQ111
cells showed a significant increase inCdk5phosphorylation induced
by SKF38393 at 5 min (8-fold; p  0.001). However, at longer
periods, no higher increase in p-Cdk5 was observed in wild-type
STHdhQ7 cells, whereas mutant STHdhQ111 cells exhibited a sus-
tained increase inCdk5phosphorylation thatwasmaximalat60min
after treatment (17-fold; p 0.001) (Fig. 4D). These data suggest
a dual role of mutant huntingtin on the Cdk5 pathway by reducing
the total expression of Cdk5 and enhancing D1R-mediated Cdk5
phosphorylation.
Finally, we investigated whether pretreatment with NMDA
modified the D1R-mediated phosphorylation of Cdk5 in wild-
type STHdhQ7 and mutant STHdhQ111 striatal cells. Exposure of
wild-type STHdhQ7 cells toNMDAbefore SKF38393 treatment did
not change the pattern of Cdk5 phosphorylation compared with
SKF38393 alone (F(1,25) 0.89; p 0.35) (Fig. 4E). However, mu-
tant STHdhQ111 cells pre-exposed toNMDAexhibited higher Cdk5
phosphorylation comparedwith those treatedwith SKF38393 alone
(F(1,25)147.07;p0.001)without significant interactionbetween
treatment and time (F(4,25) 2.21; p 0.092). These results dem-
onstrate that in the presence of mutant huntingtin, activation of
Cdk5 by D1R is potentiated by NMDAR activation.
STHdhQ111 mutant cells exhibited higher p25 levels
Conversion of p35 into p25 by Ca2-dependent calpain activa-
tion has been suggested to deregulate Cdk5 activity in several
Figure 3. JNK activation is not associated with NMDA and dopamine-mediated neurotoxicity in wild-type STHdh Q7 and
mutant STHdh Q111 striatal cells.A, RepresentativeWestern blot showing levels of p-JNK, JNK, and-tubulin as a loading control,
from wild-type (ST7/7Q) and mutant (ST111/111Q) striatal cells treated with NMDA (500M) or SKF38393 (100M) alone, or
preincubated with NMDA (30 min) before SKF38393 treatment. Total cell extracts were obtained 30 min after treatment. The
histogram represents the relative p-JNK/JNK ratio expressed as fold increase versus control cells. Values are given as mean SD
of three independent experiments. B, Wild-type (ST7/7Q) and mutant (ST111/111Q) striatal cells pretreated (1 h) with the JNK
inhibitor SP600125 (10M) were exposed to NMDA (500M) or SKF38393 (100M) alone, or preincubated with NMDA before
SKF38393 exposure. Cell survival was evaluated 24 h later by scoring the percentage of Hoechst-stained nuclei. Forty fields were
counted per condition per experiment, comprising at least 30–40 cells. Results are expressed as percentage of control (vehicle-
treated) cells, and data are the mean SD of three independent experiments performed in triplicate. ***p 0.001 treated
versus vehicle-treated wild-type cells; p 0.001 treated versus vehicle-treated mutant cells as determined by one-way
ANOVA followed by Bonferroni’s multiple comparison test.
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neurodegenerative disorders (Dhariwala and Rajadhyaksha,
2008). Indeed, calpain cleavage turns p25 into a more stable pro-
tein, which results in prolonged Cdk5 activity (Patrick et al.,
1999). To examine whether mutant huntingtin altered the levels
of p35 or its cleaved product p25, we performed immunoblot
analysis using an antibody that recognizes either p35 or p25
forms (Fig. 5A). Our results showed a significant decrease in p35
levels in mutant STHdhQ111 cells compared with those observed
in wild-type STHdhQ7 cells (2-fold; p 0.001). In contrast, the
levels of p25, which were almost undetectable in wild-type STH-
dhQ7 striatal cells, were significantly higher in mutant STH-
dhQ111 cells (2.5-fold; p  0.001). Because p25 results from
calpain activity, usingWestern blot we next measured the break-
down products of spectrin (SBDP), a well known calpain sub-
strate that yields specific products at 150/160 kDa after calpain
cleavage. Consistent with higher p25 accu-
mulation, mutant STHdhQ111 cells exhib-
ited increased levels of SBDP at 150/160
kDa compared with wild-type cells (2-
fold; p  0.05) (Fig. 5B). Given that cal-
pain activity is calciumdependent, and be-
cause of the fact that mutant STHdhQ111
cells exhibit at basal levels enhanced
NMDAR activation (Gines et al., 2003;
Seong et al., 2005), we next evaluated
whether p25 accumulation might be a
consequence of increased NMDAR-
mediated calcium influx. To test this hy-
pothesis, mutant huntingtin cells were
treated with MK-801, a specific NMDAR
antagonist that blocks calcium influx asso-
ciated to NMDAR activation or with the
calcium chelator EGTA. Immunoblot
analysis revealed that p25 levels in mutant
cells treated with MK-801 or EGTA were
lower than those observed in untreated
mutant cells (1.2-fold decrease; p 
0.01), although still significantly higher
compared with wild-type cells (2.4-
fold increase; p  0.001) (Fig. 5C). Im-
portantly, this reduction in p25 levels
parallels the increase of p35 levels (1.1-
fold increase; p  0.01) (Fig. 5C). These
data suggest that endogenous activation
of NMDAR in mutant striatal cells is not
the major contributor to p25
accumulation.
We next evaluated whether either co-
stimulation of NMDAR and D1R or single
activation induced higher accumulation of
p25. Surprisingly, compared with un-
treated cells, all treatments failed to in-
crease the accumulation of p25 any further
in both wild-type and mutant striatal cells
(Fig. 5D–F). These findings suggest that
mutant huntingtin expression is sufficient
to induce the conversion of p35 into p25
and support the idea that accumulation of
p25 in parallel with higher Cdk5 activity
may contribute to the increased vulnera-
bility ofmutant STHdhQ111 striatal cells to
NMDA and D1R activation.
Increased Cdk5 activity and tau phosphorylation in
STHdhQ111 mutant cells
Our previous results have demonstrated higher phosphorylation
of Cdk5 induced by D1R activation alone or combined by pre-
exposure to NMDA in mutant compared with wild-type striatal
cells. To determinewhether increasedCdk5 phosphorylation and
accumulation of p25 was associated to higher Cdk5 activation,
kinase activity was determined in vitro by using Cdk5 immuno-
precipitated from untreated or treated (SKF38393 alone or com-
bined with NMDA) wild-type STHdhQ7 andmutant STHdhQ111
striatal cells. Our results showed that at basal conditions mutant
striatal cells exhibited a significant increase in Cdk5 activity com-
paredwithwild-type striatal cells (2.5-fold; p 0.01) (Fig. 6A).
Interestingly, whereas NMDA exposure before SKF38393 treat-
ment did not further increase Cdk5 activity in wild-type striatal
Figure 4. NMDA receptor activation potentiates D1R-induced Cdk5 phosphorylation in mutant STHdh
Q111 cells. A, Represen-
tative Western blot showing levels of p-Cdk5, Cdk5, and -tubulin as a loading control from wild-type (ST7/7Q) and mutant
(ST111/111Q) striatal cells. B, Representative Western blot showing levels of p-Cdk5, Cdk5, and GFP and-tubulin as a loading
control from wild-type striatal cells transfected with different constructs encoding for enhanced fluorescent protein-tagged
exon-1mutant huntingtin proteinwith 23 (Q23), 72 (Q72), or 103 (Q103) CAG repeats.C–E, RepresentativeWestern blot showing
levels of p-Cdk5, Cdk5, and -tubulin as a loading control from wild-type (ST7/7Q) and mutant (ST111/111Q) cell extracts
obtained after treatmentwithNMDA500M (C), SKF38393100M (D), or a pretreatmentwithNMDAbefore SKF38393exposure
(E). Total cell extracts were obtained at different time periods (5, 15, 30, and 60 min) after treatment. The histograms represent
the relative p-Cdk5/Cdk5 ratio expressed as fold increase versus control (vehicle-treated) cells. Values are given asmean SD of
five independent experiments. A full statistical analysis by the two-wayANOVA is described in the text. **p0.01, ***p0.001
treatedversus vehicle-treatedwild-type cells; p0.05, p0.01, p0.001 treatedversus vehicle-treatedmutant
cells; #p 0.05, ##p 0.01, ###p 0.001 treatedmutant cells versus treatedwild-type cells (Bonferroni’smultiple comparison
test).
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cells compared with SKF38393 alone (1.2-fold and1.3-fold,
respectively; p  0.53), in mutant striatal cells NMDA signifi-
cantly potentiates D1R-induced Cdk5 activity (1.9-fold, p 
0.001 and 2.8-fold, p  0.001, respectively) (Fig. 6A). In sup-
port of enhanced Cdk5 activity in mutant striatal cells, Western
blot analysis using antibodies specific for phosphorylated tau
(PHF-1, Ser396 and Ser404) showed increased tau phosphoryla-
tion in basal mutant striatal cells compared with wild-type cells
without changes on total tau levels (1.5-fold increase; p 
0.05). Consistent with our results on Cdk5 activity, the levels of
tau phosphorylation in wild-type cells pretreated with NMDA
were similar than those detected in wild-type cells treated with
SKF38393 alone (1.2-fold increase and1.3-fold increase, re-
spectively; p 0.97) (Fig. 6B). In contrast, inmutant cells, higher
levels of tau phosphorylation were detected when cells were pre-
exposed to NMDA (2.6-fold and 2.1-fold, respectively; p 
0.05) (Fig. 6B). These data suggest that mutant huntingtin in-
duces enhanced Cdk5 activity that results in increased phosphor-
ylation of tau, an effect that is exacerbated by activation of D1R
alone or in combination with NMDAR.
Roscovitine ameliorates cell death evoked by SKF38393 and
NMDA treatment in STHdhQ111 cells
The previous data suggest that Cdk5 may act as a down-stream
mediator of NMDA and SKF38393 neurotoxicity in striatal cells.
To test this hypothesis, we next evaluated the effect of roscovitine,
a Cdk5 inhibitor, on NMDA and SKF38393-induced cell death.
We found that roscovitinewas able to significantly reverse the cell
death induced by NMDA, SKF38393, or both in either wild-type
andmutant huntingtin cells (Fig. 7). These findings demonstrate
that a blockade of Cdk5 by roscovitine correlates with a reduction
of cell death induced by NMDAR and D1R activation in striatal
cells and supports the involvement of aberrant Cdk5 activation in
the increased vulnerability of mutant STHdhQ111 striatal cells to
NMDA and SKF38393 treatment.
Cdk5 pathway is deregulated inHdhQ111 knock-in mice and
in HD human brain
To determine the relevance of deregulation of Cdk5 pathway
in an in vivoHDmodel, we next analyzed whether Cdk5 alter-
ation was also detected in the striatum of mutant HdhQ111
mice. We first analyzed the levels of Cdk5 in striatal brain
extracts obtained from mutant HdhQ111 mice and wild-type
HdhQ7 littermate mice at 9 months of age. In agreement with
our results on mutant striatal cells, immunoblot analysis re-
vealed a significant increase in the ratio p-Tyr 15 Cdk5/Cdk5 in
the striatum of mutant HdhQ111 mice compared with wild-
type HdhQ7 mice (2-fold; p  0.05) (Fig. 8A). Moreover,
decreased p35 expression (2-fold; p  0.01) and higher ac-
cumulation of p25 forms (2-fold; p 0.01) were detected in
Figure5. Increased p25/p35 levels inmutant STHdh Q111 striatal cells.A, RepresentativeWestern blot showing levels of p35, p25, and-tubulin as a loading control fromwild-type (ST7/7Q) and
mutant (ST111/111Q) striatal cells. B, Representative Western blot showing -spectrin and SDBP (150–160 kDa) and -tubulin as a loading control from wild-type (ST7/7Q) and mutant
(ST111/111Q) striatal cells.C, RepresentativeWesternblot showing levels of p35, p25, and-tubulin as a loading control fromwild-typeandmutant striatal cells treatedwithMK-80125Mor EGTA
400M for 6 h. Thehistograms represent the relative p35 andp25 levels expressed as fold increase versuswild-type cells. Values are given asmean SDof three independent experiments. ***p
0.001mutant cells versuswild-type cells; ##p0.01, ###p0.001 treatedversus vehicle-treatedmutant cells asdeterminedbyone-wayANOVA followedbyBonferroni’smultiple comparison test.
D–F, RepresentativeWestern blot showing p35 and p25 levels and-tubulin as a loading control fromwild-type andmutant striatal cells treatedwith NMDA 500M alone (D), SKF38393 100M
alone (E), or pretreatedwith NMDAbefore SKF38393 exposure (F ). Total extractswere obtained at different time periods (5, 15, 30, and 60min) after treatment. (n 3 independent experiments).
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mutant HdhQ111 striatal extracts compared with wild-type
HdhQ7 striatal extracts (Fig. 8A). Finally, to determine
whether increased Cdk5 phosphorylation and p25 expression
involved higher Cdk5 activity, we next examined the levels of
tau phosphorylation. Western blot analysis revealed a signifi-
cant increase of tau phosphorylation (PHF-1) in mutant
HdhQ111 striatal brain compared with wild-typeHdhQ7 striatal
brain (2-fold; p 0.01) (Fig. 8B). These results suggest that
mutant huntingtin expression enhances Cdk5 activity in vivo
by increasing Cdk5 phosphorylation and the conversion of
p35 to p25, which results in aberrant phosphorylation of tau
protein. Finally, we also investigated whether aberrant Cdk5
pathway was manifested in HD human brain. Western blot
analysis confirmed a decrease of Cdk5 in human striatal brain
samples from HD patients compared with control brains (Fig.
8C). Unfortunately, we failed to detect Cdk5 phosphorylation
(Tyr15) in human brain extracts probably because of the sen-
sitivity of this phosphorylation site to postmortem intervals
(range from 4 to 15 h for HD samples and from 4 to 23 h for
control samples). Importantly, an increase of p25/p35 levels
Figure 6. Mutant STHdh Q111 striatal cells exhibit increased Cdk5 activity associated with
higher tau phosphorylation. Wild-type (ST7/7Q) and mutant (ST111/111Q) striatal cells were
treated with SKF38393 (100M) or pretreated with NMDA (500M) before SKF38393 expo-
sure, and total cell extracts were obtained 30 min after treatment. A, In vitro kinase assay of
immunoprecipitated Cdk5 from 500g of whole-cell lysates was performed using H1 peptide
as substrate. Thehistogram represents the Cdk5 kinase activity in relative units corrected for the
protein levels of Cdk5 for each sample and refereed to control (vehicle-treated) wild-type cells.
Values are given as mean SD of three independent experiments. **p 0.01 treated versus
vehicle-treated wild-type cells; p 0.001 treated versus vehicle-treated mutant cells;
$$p  0.01 vehicle-treated mutant cells versus vehicle-treated wild-type cells; #p  0.05
NMDA plus SKF38393-treated mutant cells versus SKF38393-treated mutant cells as deter-
mined by one-way ANOVA followed by Bonferroni’s multiple comparison test. B, Representa-
tive Western blot showing total Tau (TG5) levels, phosphorylated Tau (PHF-1) levels, and
-tubulin as a loading control from wild-type and mutant striatal cells. The histogram repre-
sents the relative PHF-1/TG5 ratio expressed as fold increase versus wild-type cells. Values are
given as mean SD of three independent experiments. *p 0.05 treated versus vehicle-
treatedwild-type cells; p 0.05, p 0.01 treated versus vehicle-treatedmutant cells;
$p0.05 vehicle-treatedmutant cells versus vehicle-treatedwild-type cells; #p0.05NMDA
plus SKF38393-treated mutant cells versus SKF38393-treated mutant cells as determined by
one-way ANOVA followed by Bonferroni’s multiple comparison test.
Figure 7. Inhibition of Cdk5 kinase activity by roscovitine ameliorates STHdh Q111 cells from
cell death induced by SKF38393 and NMDA treatment. A, B, Wild-type (ST7/7Q; A) andmutant
(ST111/111Q;B) striatal cells pretreated (1 h) with the Cdk5 inhibitor roscovitine (20M)were
exposed to NMDA (500M) or SKF38393 (100M) alone, or preincubated with NMDA before
SKF38393exposure. Cell survivalwas evaluated24h later by scoring thepercentageofHoechst-
stained nuclei. Forty fields were counted per condition per experiment, comprising at least
30–40 cells. Results are expressed as percentage of control (vehicle-treated) cells, and data are
the mean  SD of three independent experiments performed in triplicate. ***p  0.001
treated versus vehicle-treated wild-type cells; $p 0.05, $$$p 0.001 roscovitine-treated
versus roscovitine-untreated wild-type cells; p  0.05, p  0.001 treated versus
vehicle-treated mutant cells; #p 0.05, ###p 0.001 roscovitine-treated versus roscovitine-
untreated mutant cells as determined by one-way ANOVA followed by Bonferroni’s multiple
comparison test.
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were also detected in HD human striatal
brains compared with control striatal
brains. Thus, HD striatal brains exhib-
ited a significant decrease in p35 expres-
sion (3-fold; p  0.05) and increased
p25 levels (4-fold; p 0.001) (Fig. 8C)
compared with control striatal brains.
These data support the view that aber-
rant Cdk5 pathway is also manifested in
HD patients and suggest a role of p25/
Cdk5 in HD pathology.
Discussion
Degeneration of medium spiny neurons
in the striatum is the main hallmark of
HD neuropathology. However, the mo-
lecular mechanism by which mutant
huntingtin toxicity causes such specific
cell death remains unknown. Our
present work demonstrates that full-
length mutant huntingtin enhances the
sensitivity of striatal cells to dopamine
leading to increased neuronal death.
This effect on neurotoxicity is mediated
by D1 but not D2 receptors as demon-
strated by using specific dopamine-
receptor agonists. Thus, the direct acti-
vation of D1R by SKF38393 revealed a
higher dose–response reduction in cell
survival in mutant STHdhQ111 than in
wild-type STHdhQ7 cells, an effect that
was mostly reverted by the selective D1
antagonist SCH23390. The lack of cell
death in the presence of the D2 agonist quinpirole indicates
that the neurotoxic effect of dopamine in knock-in mutant
striatal cells is mainly associated with D1R activation. These
results agree with previous reports indicating the role of D1R
in striatal neuronal loss. It has been proposed that dopamine,
by acting through activation of D1R and auto-oxidation,
causes striatal neurotoxicity by inducing the neuronal expres-
sion and activity of inducible nitric oxide synthase (Wersinger
et al., 2004). Moreover, dopamine through D1R potentiates
glutamate-induced toxicity in cultured striatal cells from
YAC128 HD mice (Tang et al., 2007). However, the involve-
ment of D2R in HD pathology cannot be completely ruled out
because dopamine via D2 receptors enhances mutant hunting-
tin aggregation and mitochondrial dysfunction in exon-1 HD
mouse models (Charvin et al., 2005; Benchoua et al., 2008).
Therefore, it is possible that at early disease stages that is in the
absence of mutant huntingtin cleavage and aggregate forma-
tion, dopamine toxicity acts primarily via D1R whereas later in
the disease progress altered D1 and D2 receptor signaling con-
tribute to HD pathology.
It is well known that glutamate and dopamine receptors reg-
ulate striatal neuronal function by interacting and modulating
each other. Specifically, an association between NMDAR and
D1R has been reported, although the nature of this interaction
remains unclear (Scott et al., 2002; Salter, 2003; Cepeda and Le-
vine, 2006;Missale et al., 2006). Here, we have demonstrated that
NMDA potentiates D1R-induced cell death in mutant STH-
dhQ111 cells but not in wild-type STHdhQ7 cells. We have tested
toxic NMDA concentrations, which induce similar cell death in
wild-type and mutant cells and low NMDA concentrations,
Figure 9. Increased sensitivity of mutant huntingtin striatal cells to glutamate and dopa-
mine receptor activation involves enhanced Cdk5 activity. Hypotheticalmodel to depict the link
between neurotoxicity induced by dopamine and glutamate receptor activation and the Cdk5
pathway in HD. Enhanced activation of NMDAR and D1R induced bymutant huntingtin leads to
deregulation of calcium homeostasis (Cepeda et al., 2001; Seong et al., 2005; Starling et al.,
2005; Tang et al., 2007). Increased intracellular calcium in turn leads to higher calpain activity
that results in enhanced cleavage of p35 into p25 (Lee et al., 2000). In addition, as our data
demonstrate, activation of NMDAR may potentiate D1R-mediated phosphorylation of Cdk5 at
Tyr 15, which has been shown to regulate Cdk5-induced neurotoxicity (Lin et al., 2007). The
generation of p-Cdk5/p25 complexes implies Cdk5 hyperactivation that is responsible for the
phosphorylation of new substrates such as tau protein. Now, hyperphosphorylation of tau in
concert with unknown yet down-stream p25/Cdk5 effectors might contribute to striatal cell
death and dysfunction and therefore to HD neuropathology. The model is supported by the
capacity of roscovitine, a Cdk5 inhibitor, to prevent cellular death induced by NMDAR and D1R
activation.
Figure 8. Cdk5 pathway is altered in HD knock-inmice and HD human brain.A, RepresentativeWestern blot showing levels of
p-Cdk5, Cdk5, p35, p25, and-tubulin as a loading control from striatal extracts of wild-typeHdh Q7 andmutantHdh Q111mice at
9months of age.B, RepresentativeWestern blot showing levels of total Tau (TG5), phosphorylated Tau (PHF-1), and-tubulin as
a loading control from striatal extracts of wild-type Hdh Q7 and mutant Hdh Q111 mice at 9 months of age. Values are given as
mean SDof three independent samples. **p0.01 as determinedby Student’s t test.C, RepresentativeWesternblot showing
levels of total Cdk5, p35, p25, and-tubulin as a loading control from human brain striatal samples of control (n 3) and HD
patients (n 3). Scatter plots represent the relative levels of Cdk5, p35, and p25. The higher value obtained in control brain
extracts was set as 1.
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which, per se, are not toxic (Xifro´ et al., 2008). Notably, either
toxic or subtoxic NMDA concentrations enhanced the effect in
cell death mediated by SKF38393 only in mutant STHdhQ111
cells. These results agree with previous studies showing that glu-
tamate and dopamine act synergistically to induce degeneration
of striatal cells in YAC128HDmouse models (Tang et al., 2007).
Altogether, our data suggest that mutant huntingtin alters the
dopaminergic and glutamatergic signaling not only by affecting
NMDAR and D1R but also by altering the cross-talk between
both pathways. Consequently, to gain a better understanding of
howmutant huntingtin increases the vulnerability of striatal cells
to neurotoxicity, we focused on defining the molecular mecha-
nisms that underlie the toxic effect of NMDAR and D1R activa-
tion on striatal cell survival.
Recent studies have identified Cdk5 as mediator of dopami-
nergic neuronal loss in mouse models of Parkinson’s disease be-
cause inhibition of Cdk5 reduces neurodegeneration and behav-
ior disturbances in these mouse models (Smith et al., 2003, 2006;
Przedborski, 2007). Moreover, it has been demonstrated that
Cdk5 can regulate NMDAR signaling by direct phosphorylation
of NR2A andNR2B subunits or indirectly via phosphorylation of
postsynaptic density-95 (Morabito et al., 2004; Zhang et al.,
2008). Therefore, it is reasonable to hypothesize a role forCdk5 in
the increased vulnerability of mutant huntingtin striatal cells to
NMDAR and D1R activation.
We have examined two important features of Cdk5 activa-
tion related to its pro-apoptotic function: the levels of Tyr 15
phosphorylation (Lin et al., 2007) and the accumulation of
p25 as a result of calpain-mediated p35 cleavage (Kusakawa et
al., 2000; Lee et al., 2000). Our results in knock-in striatal cells
define a new role of mutant huntingtin as modulator of the
Cdk5 pathway by (1) decreasing Cdk5 expression and increas-
ing the levels of phosphorylated Tyr 15-Cdk5 and (2) by in-
creasing the conversion of p35 into p25, which in turn results
in enhanced Cdk5 activity. Moreover, we have demonstrated a
polyQ-dependent reduction of Cdk5 expression together with
an increase in Tyr 15-Cdk5 phosphorylation in striatal cells.
These data support the idea of a direct role of mutant hunting-
tin in Cdk5 changes rather than a secondary consequence of
mutant huntingtin toxicity. Consistent with the results ob-
tained in the knock-in striatal cell line, we also found deregu-
lation of Cdk5 in HdhQ111 knock-in mice and HD human
brain. Our studies demonstrate an increased of p-Tyr 15-Cdk5/
Cdk5 ratio and a significant accumulation of p25 together
with reduced p35 expression in the striatum of HdhQ111 mu-
tant mice and HD human brain. In agreement with these re-
sults, Anne et al. (2007) have reported reduced levels of Cdk5
and p35 in HD human brain, although no data on p25 accu-
mulation was reported. These data are relevant because it has
been demonstrated a protective role of p35/Cdk5 complexes
in HD. Phosphorylation of mutant huntingtin by p35/Cdk5
complexes reduces huntingtin cleavage by caspases resulting
in attenuated aggregate formation and toxicity (Luo et al.,
2005). Moreover, phosphorylation of wild-type huntingtin by
Cdk5 protects striatal cells against DNA damage (Anne et al.,
2007). Both reports speculate that loss of p35/Cdk5 function
may have detrimental consequences for HD pathology. There-
fore, our novel results demonstrating an accumulation of p25
in HD mouse brain and striatal cell models and in HD human
brain might be relevant to explain the apparent dual role of
Cdk5 in HD pathology. Indeed, it is well established the role of
p25 as a cell death inductor (Cruz and Tsai, 2004; Dhariwala
and Rajadhyaksha, 2008). Thus, neurotoxicity induced by
-amyloid, ischemia, or MPTP causes aberrant Cdk5 activity
through the generation and accumulation of p25 (Cruz and
Tsai, 2004; Dhariwala and Rajadhyaksha, 2008). Furthermore,
this truncated p25 form relocalizes Cdk5 activity with the con-
sequent alteration of Cdk5 substrate specificity (Patrick et al.,
1999; Ko et al., 2001; Bian et al., 2002). Actually, elevated Cdk5
activity accumulation of p25 and hyperphosphorylated tau
have been described in brain of AD patients (Cruz and Tsai,
2004; Dhariwala and Rajadhyaksha, 2008). Notably, our stud-
ies have identified tau as a downstream target of aberrant Cdk5
activity in HDmouse and striatal cell models. The specific role
of tau in HD pathology remains to be elucidated. However,
given evidence of impaired axonal trafficking in HD (Truant
et al., 2006), it seems reasonable to speculate that altered tau
may be involved in the vesicular trafficking deficiencies asso-
ciated to HD pathology.
Collectively, our results clearly demonstrate that mutant
huntingtin deregulates Cdk5 pathway. However, one impor-
tant question is to determine whether aberrant Cdk5 activity
plays a role in the increased sensitivity of mutant huntingtin
cells to NMDAR and D1R activation. Indeed, our data indicate
that deregulated Cdk5 pathway might be instrumental in the
HD neurodegenerative process by increasing the vulnerability
of striatal cells to dopamine and glutamate inputs. This con-
clusion is supported by the following observations: first,
SKF38393 induced higher Cdk5 phosphorylation and activity
in mutant cells than in wild-type cells. Second, exposure of
mutant cells to NMDA before SKF38393 induced higher levels
of Cdk5 phosphorylation and activity than in wild-type cells
or mutant cells treated with SKF38393 alone. Third, compared
with wild-type cells, increased levels of phosphorylated tau
were detected in mutant striatal cells treated with SKF38393
alone or pre-exposed to NMDA. Therefore, these data dem-
onstrate that mutant huntingtin increases the sensitivity of
striatal cells to dopamine and glutamate inputs by altering a
common NMDAR and D1R downstream pathway such is
Cdk5. Supporting this conclusion are the findings that the
inhibition of Cdk5 activity by roscovitine mainly prevented
striatal cell death induced by NMDA, SKF38393, or both.
However, because neuronal loss induced by NMDA and
SKF38393 cotreatment was not fully prevented by roscovitine
in mutant cells, we can speculate that additional mechanism
independent of Cdk5 might be involved in the toxicity associ-
ated to NMDAR and D1R activation.
Based on these findings, an attractive model of striatal cell
death is one in which aberrant Cdk5 activity (Fig. 6) as a result
of enhanced Cdk5 phosphorylation at Tyr 15 (Fig. 4) and p25
accumulation (Fig. 5) might sensitize mutant huntingtin stri-
atal cells to NMDAR and D1R activation. Therefore, once
NMDAR and D1R were activated, both receptors might act
coordinately to promote calcium homeostasis deregulation
(Cepeda et al., 2001; Starling et al., 2005; Tang et al., 2007)
with the consequent mitochondrial depolarization and
caspase activation (Zeron et al., 2002, 2004). In addition, as
our data demonstrate, the activation of NMDAR may further
potentiate D1R-mediated phosphorylation of Cdk5, leading to
the generation of p-Cdk5/p25 complexes and enhanced Cdk5
activity. Sustained Cdk5 activity may now target for phos-
phorylation different substrates such as tau or additional rec-
ognized Cdk5 effectors (Gong et al., 2003; Lee et al., 2007) and
contribute to striatal cell death in HD.
In conclusion, our results provide evidence that aberrant
Cdk5 activity is involved in the increased sensitivity of mutant
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huntingtin striatal cells to dopamine and glutamate inputs and
reveal p25/Cdk5 complexes as potential candidates for future
pharmacological intervention in HD (Fig. 9).
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